Four Pillars of Heart Failure Therapy

EP: 1.Identifying Key Risk Factors for Heart Failure

EP: 2.Socioeconomic Factors Impacting Development of Cardiac Disease

EP: 3.Distinguishing Between Heart Failure Classifications

EP: 4.Staging Heart Failure and the Importance of Early Diagnosis

EP: 5.The Role of the Primary Care Physician in Heart Failure Management

Now Viewing

EP: 6.Four Pillars of Heart Failure Therapy

EP: 7.Selecting Optimal First-line Therapy for Patients Diagnosed with Heart Failure

EP: 8.Key Takeaways From Heart Failure Clinical Trials

EP: 9.Navigating the Patient Journey Through Heart Failure Diagnosis

EP: 10.Strategies for Treating Preserved Ejection Fraction (HFpEF)

EP: 11.Treatment Optimization Challenges Associated With Heart Failure

EP: 12.Financial Barriers Impeding Optimal Heart Failure Treatment

EP: 13.Trajectory of Heart Failure Treatment Strategies

EP: 14.Key Takeaways from Experts in Heart Failure Management

This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. Axsom, MD, outlines the 4 pillars of guideline-directed medical therapy for symptomatic heart failure with reduced ejection fraction (HFrEF), which also applies to midrange ejection fraction (EF): angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); evidence-based beta blockers (metoprolol succinate, bisoprolol, carvedilol); mineralocorticoid receptor antagonists (MRAs; spironolactone, eplerenone); and sodium-glucose cotransporter-2 (SGLT2) inhibitors (dapagliflozin, empagliflozin). The specific beta blockers reduce 1-year mortality by 36% based on randomized controlled trial data. For heart failure with preserved ejection fraction (HFpEF), treatment focuses on managing comorbidities until EF declines below 60% to 65%. Implementation and adherence to guideline-directed medical therapy remains a challenge. The classification system helps guide evidence-based treatments for HFrEF, while HFpEF management is more limited but evolving.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.